Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D.

Cancer. 2016 Apr 1;122(7):1108-15. doi: 10.1002/cncr.29888. Epub 2016 Jan 27.

2.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK.

N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.

3.

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J, Stockdale A, Rashid S, Nathan P, Chowdury S.

Eur J Cancer. 2012 Nov;48(17):3171-6. doi: 10.1016/j.ejca.2012.05.022. Epub 2012 Jul 4.

PMID:
22766517
4.

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C, Pandite L.

Eur J Cancer. 2016 Jan;53:96-104. doi: 10.1016/j.ejca.2015.10.006. Epub 2015 Dec 15.

PMID:
26702763
5.

Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.

Delea TE, Amdahl J, Diaz J, Nakhaipour HR, Hackshaw MD.

J Manag Care Spec Pharm. 2015 Jan;21(1):46-54, 54a-b.

6.

Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.

Kim JH, Park I, Lee JL.

Cancer Chemother Pharmacol. 2016 Aug;78(2):325-32. doi: 10.1007/s00280-016-3093-8. Epub 2016 Jun 21.

PMID:
27324136
7.

Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.

Capri S, Porta C, Delea TE.

Clin Ther. 2017 Mar;39(3):567-580.e2. doi: 10.1016/j.clinthera.2017.01.017. Epub 2017 Feb 9.

PMID:
28189363
8.

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Xie M, He CS, Huang JK, Lin QZ.

Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21.

PMID:
25618828
9.

Pazopanib outscores sunitinib on tolerability.

[No authors listed]

Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.

10.

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA.

Clin Genitourin Cancer. 2013 Sep;11(3):270-5. doi: 10.1016/j.clgc.2013.04.006. Epub 2013 May 9.

PMID:
23665131
11.

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.

Br J Cancer. 2012 May 8;106(10):1587-90. doi: 10.1038/bjc.2012.149.

12.

Benefits of pazopanib over sunitinib for renal cell carcinoma.

Granovetter M.

Lancet Oncol. 2016 Mar;17(3):e93. doi: 10.1016/S1470-2045(16)00081-4. Epub 2016 Feb 5. No abstract available.

PMID:
26853821
13.

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D.

J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31.

PMID:
24687826
14.

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.

Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

Adv Ther. 2017 Nov;34(11):2452-2465. doi: 10.1007/s12325-017-0628-2. Epub 2017 Oct 26.

15.

Health care costs among renal cancer patients using pazopanib and sunitinib.

Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD.

J Manag Care Spec Pharm. 2015 Jan;21(1):37-44, 44a-d.

16.

Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].

Trump D.

Urol Oncol. 2016 May;34(5):251. doi: 10.1016/j.urolonc.2015.03.015. Epub 2015 Apr 30.

PMID:
25937427
17.
18.

First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.

Schmidinger M, Wittes J.

Curr Opin Urol. 2015 Sep;25(5):395-401. doi: 10.1097/MOU.0000000000000207. Review.

PMID:
26148069
19.
20.

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.

Amdahl J, Diaz J, Sharma A, Park J, Chandiwana D, Delea TE.

PLoS One. 2017 Jun 21;12(6):e0175920. doi: 10.1371/journal.pone.0175920. eCollection 2017.

Supplemental Content

Support Center